Thomas Reiberger
@reibergerthomas.bsky.social
Professor of Hepatology @MedUni_Wien
Director CD-Lab for #PortalHypertension & #LiverFibrosis
Adjunct PI @cemm-vienna.bsky.social
Head #KFG #MOTION funded by @lbg.ac.at
Scientific Secretary @bavenocoop.bsky.social
Director CD-Lab for #PortalHypertension & #LiverFibrosis
Adjunct PI @cemm-vienna.bsky.social
Head #KFG #MOTION funded by @lbg.ac.at
Scientific Secretary @bavenocoop.bsky.social
Today these two fellows rocked their VENIA DOCENDI
🎓David CHROMY : STIs & #HepatitisC
🎓Mathias JACHS : NITs in #PortalHypertension
my personal highlights:
@mathiasjachs.bsky.social in @lancetgastrohep.bsky.social
Spleen Stiffness
🔗 t.ly/DysXB
Chromy in #UEGJ
DAAs in acute #HCV
🔗 t.ly/nIZ2a
🎓David CHROMY : STIs & #HepatitisC
🎓Mathias JACHS : NITs in #PortalHypertension
my personal highlights:
@mathiasjachs.bsky.social in @lancetgastrohep.bsky.social
Spleen Stiffness
🔗 t.ly/DysXB
Chromy in #UEGJ
DAAs in acute #HCV
🔗 t.ly/nIZ2a
September 29, 2025 at 7:57 PM
Today these two fellows rocked their VENIA DOCENDI
🎓David CHROMY : STIs & #HepatitisC
🎓Mathias JACHS : NITs in #PortalHypertension
my personal highlights:
@mathiasjachs.bsky.social in @lancetgastrohep.bsky.social
Spleen Stiffness
🔗 t.ly/DysXB
Chromy in #UEGJ
DAAs in acute #HCV
🔗 t.ly/nIZ2a
🎓David CHROMY : STIs & #HepatitisC
🎓Mathias JACHS : NITs in #PortalHypertension
my personal highlights:
@mathiasjachs.bsky.social in @lancetgastrohep.bsky.social
Spleen Stiffness
🔗 t.ly/DysXB
Chromy in #UEGJ
DAAs in acute #HCV
🔗 t.ly/nIZ2a
Our @GeorgKRAMER myself & @CristinaRIPOLL perspective on staging of #Decompensated #Cirrhosis
- this was a Letter ✉️ to @jhepatology.bsky.social in response to an article by Dr. Verma @rajivjalan.bsky.social et al
#NonAcuteDecompensation (NAD) 🔗 t.ly/mc4VG
- who responded w/ an interesting proposal
- this was a Letter ✉️ to @jhepatology.bsky.social in response to an article by Dr. Verma @rajivjalan.bsky.social et al
#NonAcuteDecompensation (NAD) 🔗 t.ly/mc4VG
- who responded w/ an interesting proposal
September 28, 2025 at 7:14 PM
Our @GeorgKRAMER myself & @CristinaRIPOLL perspective on staging of #Decompensated #Cirrhosis
- this was a Letter ✉️ to @jhepatology.bsky.social in response to an article by Dr. Verma @rajivjalan.bsky.social et al
#NonAcuteDecompensation (NAD) 🔗 t.ly/mc4VG
- who responded w/ an interesting proposal
- this was a Letter ✉️ to @jhepatology.bsky.social in response to an article by Dr. Verma @rajivjalan.bsky.social et al
#NonAcuteDecompensation (NAD) 🔗 t.ly/mc4VG
- who responded w/ an interesting proposal
❓Does #Smoking matter in #Cirrhosis❓
@benedikthofer.bsky.social
of @meduniwien.ac.at
demonstrates that indeed smoking
📈 triggers 🔥 inflammation & 🩸angiogenesis
🦀 leads to extrahepatic cancer
🦀 and tends to increase risk of #livercancer #HCC
📕 @LiverInt
🔗 t.ly/8Vr-0
@benedikthofer.bsky.social
of @meduniwien.ac.at
demonstrates that indeed smoking
📈 triggers 🔥 inflammation & 🩸angiogenesis
🦀 leads to extrahepatic cancer
🦀 and tends to increase risk of #livercancer #HCC
📕 @LiverInt
🔗 t.ly/8Vr-0
September 3, 2025 at 9:52 AM
❓Does #Smoking matter in #Cirrhosis❓
@benedikthofer.bsky.social
of @meduniwien.ac.at
demonstrates that indeed smoking
📈 triggers 🔥 inflammation & 🩸angiogenesis
🦀 leads to extrahepatic cancer
🦀 and tends to increase risk of #livercancer #HCC
📕 @LiverInt
🔗 t.ly/8Vr-0
@benedikthofer.bsky.social
of @meduniwien.ac.at
demonstrates that indeed smoking
📈 triggers 🔥 inflammation & 🩸angiogenesis
🦀 leads to extrahepatic cancer
🦀 and tends to increase risk of #livercancer #HCC
📕 @LiverInt
🔗 t.ly/8Vr-0
🌍 #WorldHepatitisDay #2025
🇦🇹 contributions to understanding & Elimination of #Hepatitis
1⃣ #HBV-ART in #HIV 🔗 t.ly/6TXxR
2⃣ Curing #HCV in #HIV 🔗 t.ly/FiLPq
3⃣ Eliminate #HCV in 🇦🇹AT 🔗 t.ly/CBw3o
4⃣ Followup after #HCV cure 🔗 t.ly/KvSrs
🇦🇹 contributions to understanding & Elimination of #Hepatitis
1⃣ #HBV-ART in #HIV 🔗 t.ly/6TXxR
2⃣ Curing #HCV in #HIV 🔗 t.ly/FiLPq
3⃣ Eliminate #HCV in 🇦🇹AT 🔗 t.ly/CBw3o
4⃣ Followup after #HCV cure 🔗 t.ly/KvSrs
July 28, 2025 at 1:54 PM
🌍 #WorldHepatitisDay #2025
🇦🇹 contributions to understanding & Elimination of #Hepatitis
1⃣ #HBV-ART in #HIV 🔗 t.ly/6TXxR
2⃣ Curing #HCV in #HIV 🔗 t.ly/FiLPq
3⃣ Eliminate #HCV in 🇦🇹AT 🔗 t.ly/CBw3o
4⃣ Followup after #HCV cure 🔗 t.ly/KvSrs
🇦🇹 contributions to understanding & Elimination of #Hepatitis
1⃣ #HBV-ART in #HIV 🔗 t.ly/6TXxR
2⃣ Curing #HCV in #HIV 🔗 t.ly/FiLPq
3⃣ Eliminate #HCV in 🇦🇹AT 🔗 t.ly/CBw3o
4⃣ Followup after #HCV cure 🔗 t.ly/KvSrs
REMEMBERING PROFESSOR JAUME BOSCH
President of Bavneo @bavenocoop.bsky.social
Friend and Mentor to many
President of Bavneo @bavenocoop.bsky.social
Friend and Mentor to many
July 17, 2025 at 8:36 AM
REMEMBERING PROFESSOR JAUME BOSCH
President of Bavneo @bavenocoop.bsky.social
Friend and Mentor to many
President of Bavneo @bavenocoop.bsky.social
Friend and Mentor to many
🎂 30Y of .mp3 🎵
created @ Frauenhofer Institute 🔗 t.ly/f6A1t
by 🧑🎓 Karlheinz Brandenburg 🔗 t.ly/8vojd
🙏 for good vibes when i grew up
♻️ Napster 🔗 t.ly/lqPRP
⏯️ Winamp 🔗 t.ly/_sR05
created @ Frauenhofer Institute 🔗 t.ly/f6A1t
by 🧑🎓 Karlheinz Brandenburg 🔗 t.ly/8vojd
🙏 for good vibes when i grew up
♻️ Napster 🔗 t.ly/lqPRP
⏯️ Winamp 🔗 t.ly/_sR05
July 14, 2025 at 9:01 AM
🎂 30Y of .mp3 🎵
created @ Frauenhofer Institute 🔗 t.ly/f6A1t
by 🧑🎓 Karlheinz Brandenburg 🔗 t.ly/8vojd
🙏 for good vibes when i grew up
♻️ Napster 🔗 t.ly/lqPRP
⏯️ Winamp 🔗 t.ly/_sR05
created @ Frauenhofer Institute 🔗 t.ly/f6A1t
by 🧑🎓 Karlheinz Brandenburg 🔗 t.ly/8vojd
🙏 for good vibes when i grew up
♻️ Napster 🔗 t.ly/lqPRP
⏯️ Winamp 🔗 t.ly/_sR05
Drs. @LukasHARTL and @MarleneHINTERSTEININGER of @meduniwien.ac.at showed in @CGH @AGA that
adding the #Vasopressin #ADH Biomarker #Copeptin to the MELD score improves prognostication of patients with #cirrhosis #ACLD
📖 the full study 🔗 t.ly/11GOg
@easlnews.bsky.social @bavenocoop.bsky.social
adding the #Vasopressin #ADH Biomarker #Copeptin to the MELD score improves prognostication of patients with #cirrhosis #ACLD
📖 the full study 🔗 t.ly/11GOg
@easlnews.bsky.social @bavenocoop.bsky.social
July 6, 2025 at 8:05 AM
Drs. @LukasHARTL and @MarleneHINTERSTEININGER of @meduniwien.ac.at showed in @CGH @AGA that
adding the #Vasopressin #ADH Biomarker #Copeptin to the MELD score improves prognostication of patients with #cirrhosis #ACLD
📖 the full study 🔗 t.ly/11GOg
@easlnews.bsky.social @bavenocoop.bsky.social
adding the #Vasopressin #ADH Biomarker #Copeptin to the MELD score improves prognostication of patients with #cirrhosis #ACLD
📖 the full study 🔗 t.ly/11GOg
@easlnews.bsky.social @bavenocoop.bsky.social
The #HEPEX Hepatic Experimental Lab at @meduniwien.ac.at and @cemm.oeaw.ac.at works on Disease-driving #Pathomechanisms in #Liver #Fibrosis & #PortalHypertension
🕸️ #Macrophages in #Fibrosis Resolution
🤖 #MachineLearning & #Pathomics in #LiverHistology
🦠 #Gut-Liver-Axis
🩸 #Anticoagulation
🕸️ #Macrophages in #Fibrosis Resolution
🤖 #MachineLearning & #Pathomics in #LiverHistology
🦠 #Gut-Liver-Axis
🩸 #Anticoagulation
June 19, 2025 at 1:59 PM
The #HEPEX Hepatic Experimental Lab at @meduniwien.ac.at and @cemm.oeaw.ac.at works on Disease-driving #Pathomechanisms in #Liver #Fibrosis & #PortalHypertension
🕸️ #Macrophages in #Fibrosis Resolution
🤖 #MachineLearning & #Pathomics in #LiverHistology
🦠 #Gut-Liver-Axis
🩸 #Anticoagulation
🕸️ #Macrophages in #Fibrosis Resolution
🤖 #MachineLearning & #Pathomics in #LiverHistology
🦠 #Gut-Liver-Axis
🩸 #Anticoagulation
@who.int has set Elimination of
🦠 #ViralHepatitis #B #C as a global goal for 2030
#Prisons remain a Hot ♨️ Spot for #HepC #HCV
In Vienna 🇦🇹 we focus on the incarcerated risk population
and offer onsite screening and treatment
@worldhepalliance.bsky.social
@easlnews.bsky.social
🦠 #ViralHepatitis #B #C as a global goal for 2030
#Prisons remain a Hot ♨️ Spot for #HepC #HCV
In Vienna 🇦🇹 we focus on the incarcerated risk population
and offer onsite screening and treatment
@worldhepalliance.bsky.social
@easlnews.bsky.social
June 17, 2025 at 11:36 AM
@who.int has set Elimination of
🦠 #ViralHepatitis #B #C as a global goal for 2030
#Prisons remain a Hot ♨️ Spot for #HepC #HCV
In Vienna 🇦🇹 we focus on the incarcerated risk population
and offer onsite screening and treatment
@worldhepalliance.bsky.social
@easlnews.bsky.social
🦠 #ViralHepatitis #B #C as a global goal for 2030
#Prisons remain a Hot ♨️ Spot for #HepC #HCV
In Vienna 🇦🇹 we focus on the incarcerated risk population
and offer onsite screening and treatment
@worldhepalliance.bsky.social
@easlnews.bsky.social
🇦🇹 Austrian GI/Liver Meeting 2025
3 rising 🌟 stars of our research group #MOTION
@crgmotion.bsky.social @meduniwien.ac.at presented
posters on hot 🔥 topics in #Hepatology
- Clinical Course of #NAD non-acute decompensation
- #SpleenStiffness in #PortalHypertension
- #Ultrasound Elastography in MASLD
3 rising 🌟 stars of our research group #MOTION
@crgmotion.bsky.social @meduniwien.ac.at presented
posters on hot 🔥 topics in #Hepatology
- Clinical Course of #NAD non-acute decompensation
- #SpleenStiffness in #PortalHypertension
- #Ultrasound Elastography in MASLD
June 15, 2025 at 7:53 PM
🇦🇹 Austrian GI/Liver Meeting 2025
3 rising 🌟 stars of our research group #MOTION
@crgmotion.bsky.social @meduniwien.ac.at presented
posters on hot 🔥 topics in #Hepatology
- Clinical Course of #NAD non-acute decompensation
- #SpleenStiffness in #PortalHypertension
- #Ultrasound Elastography in MASLD
3 rising 🌟 stars of our research group #MOTION
@crgmotion.bsky.social @meduniwien.ac.at presented
posters on hot 🔥 topics in #Hepatology
- Clinical Course of #NAD non-acute decompensation
- #SpleenStiffness in #PortalHypertension
- #Ultrasound Elastography in MASLD
📈 Activation of🩸#Vasopressin System in #Cirrhosis tries to compensate for 🫀 #hemodynamic & 💧#sodium #fluid abnormalities
Drs. HARTL & HINTERSTEININGER of @meduniwien.ac.at
in 🤝with efclif.com show in📕 #CGH
🔗 t.ly/joCs5
▶️ #Vasopressin biomarker #COPEPTIN predicts #ACLF in cirrhosis
Drs. HARTL & HINTERSTEININGER of @meduniwien.ac.at
in 🤝with efclif.com show in📕 #CGH
🔗 t.ly/joCs5
▶️ #Vasopressin biomarker #COPEPTIN predicts #ACLF in cirrhosis
June 6, 2025 at 7:40 AM
📈 Activation of🩸#Vasopressin System in #Cirrhosis tries to compensate for 🫀 #hemodynamic & 💧#sodium #fluid abnormalities
Drs. HARTL & HINTERSTEININGER of @meduniwien.ac.at
in 🤝with efclif.com show in📕 #CGH
🔗 t.ly/joCs5
▶️ #Vasopressin biomarker #COPEPTIN predicts #ACLF in cirrhosis
Drs. HARTL & HINTERSTEININGER of @meduniwien.ac.at
in 🤝with efclif.com show in📕 #CGH
🔗 t.ly/joCs5
▶️ #Vasopressin biomarker #COPEPTIN predicts #ACLF in cirrhosis
#LiverSky
📘 JOURNAL OF HEPATOLOGY #JHEPATOL
@jhepatology.bsky.social
is the flagshipjournal of 🇪🇺 #EASL @easlnews.bsky.social
📈 Impact Factor of 26.8 ➡️ 2.1% 🔝Percentile
Consider to submit your #Liver #Research
🔗 www.journal-of-hepatology.eu
@heinerwedemeyer.bsky.social
@docberza.bsky.social
📘 JOURNAL OF HEPATOLOGY #JHEPATOL
@jhepatology.bsky.social
is the flagshipjournal of 🇪🇺 #EASL @easlnews.bsky.social
📈 Impact Factor of 26.8 ➡️ 2.1% 🔝Percentile
Consider to submit your #Liver #Research
🔗 www.journal-of-hepatology.eu
@heinerwedemeyer.bsky.social
@docberza.bsky.social
June 3, 2025 at 9:19 AM
#LiverSky
📘 JOURNAL OF HEPATOLOGY #JHEPATOL
@jhepatology.bsky.social
is the flagshipjournal of 🇪🇺 #EASL @easlnews.bsky.social
📈 Impact Factor of 26.8 ➡️ 2.1% 🔝Percentile
Consider to submit your #Liver #Research
🔗 www.journal-of-hepatology.eu
@heinerwedemeyer.bsky.social
@docberza.bsky.social
📘 JOURNAL OF HEPATOLOGY #JHEPATOL
@jhepatology.bsky.social
is the flagshipjournal of 🇪🇺 #EASL @easlnews.bsky.social
📈 Impact Factor of 26.8 ➡️ 2.1% 🔝Percentile
Consider to submit your #Liver #Research
🔗 www.journal-of-hepatology.eu
@heinerwedemeyer.bsky.social
@docberza.bsky.social
🚨 #LiverSky
interested in #Cirrhosis and #PortalHypertension
➡️ Read the #Baveno VII Consensus
🔗 t.ly/1P7Ta
Get Ready and Register for the #Baveno VIII Consensus
📆 27-28 MARCH 2026
🔗 baveno8.org
@bavenocoop.bsky.social
@easlnews.bsky.social @aasldnews.bsky.social
interested in #Cirrhosis and #PortalHypertension
➡️ Read the #Baveno VII Consensus
🔗 t.ly/1P7Ta
Get Ready and Register for the #Baveno VIII Consensus
📆 27-28 MARCH 2026
🔗 baveno8.org
@bavenocoop.bsky.social
@easlnews.bsky.social @aasldnews.bsky.social
June 1, 2025 at 1:40 PM
🚨 #LiverSky
interested in #Cirrhosis and #PortalHypertension
➡️ Read the #Baveno VII Consensus
🔗 t.ly/1P7Ta
Get Ready and Register for the #Baveno VIII Consensus
📆 27-28 MARCH 2026
🔗 baveno8.org
@bavenocoop.bsky.social
@easlnews.bsky.social @aasldnews.bsky.social
interested in #Cirrhosis and #PortalHypertension
➡️ Read the #Baveno VII Consensus
🔗 t.ly/1P7Ta
Get Ready and Register for the #Baveno VIII Consensus
📆 27-28 MARCH 2026
🔗 baveno8.org
@bavenocoop.bsky.social
@easlnews.bsky.social @aasldnews.bsky.social
⚠️ #Hepatitis B Elimination
@easlnews.bsky.social @who.int @lancetgastrohep.bsky.social
😑 73% met #WHO criterion of ≤0.5% HBsAg prevalence
😑 67% have universal #HBV birth vaccinations
☹️ Suboptimal #WHO diagnosis coverage target of 60%
😱 no country met #HBV treatment target
@easlnews.bsky.social @who.int @lancetgastrohep.bsky.social
😑 73% met #WHO criterion of ≤0.5% HBsAg prevalence
😑 67% have universal #HBV birth vaccinations
☹️ Suboptimal #WHO diagnosis coverage target of 60%
😱 no country met #HBV treatment target
May 25, 2025 at 11:30 AM
⚠️ #Hepatitis B Elimination
@easlnews.bsky.social @who.int @lancetgastrohep.bsky.social
😑 73% met #WHO criterion of ≤0.5% HBsAg prevalence
😑 67% have universal #HBV birth vaccinations
☹️ Suboptimal #WHO diagnosis coverage target of 60%
😱 no country met #HBV treatment target
@easlnews.bsky.social @who.int @lancetgastrohep.bsky.social
😑 73% met #WHO criterion of ≤0.5% HBsAg prevalence
😑 67% have universal #HBV birth vaccinations
☹️ Suboptimal #WHO diagnosis coverage target of 60%
😱 no country met #HBV treatment target
⚠️ #Hepatitis C Elimination
@easlnews.bsky.social @who.int
@lancetgastrohep.bsky.social
😑 not all countries have national HCV action plans
☹️ 36% have (partial) restrictions on curative #HCV treatments
😑 30% met HCV #WHO diagnosis coverage target of 60%
☹️ only 15% met HCV #WHO treatment target
@easlnews.bsky.social @who.int
@lancetgastrohep.bsky.social
😑 not all countries have national HCV action plans
☹️ 36% have (partial) restrictions on curative #HCV treatments
😑 30% met HCV #WHO diagnosis coverage target of 60%
☹️ only 15% met HCV #WHO treatment target
May 25, 2025 at 11:23 AM
⚠️ #Hepatitis C Elimination
@easlnews.bsky.social @who.int
@lancetgastrohep.bsky.social
😑 not all countries have national HCV action plans
☹️ 36% have (partial) restrictions on curative #HCV treatments
😑 30% met HCV #WHO diagnosis coverage target of 60%
☹️ only 15% met HCV #WHO treatment target
@easlnews.bsky.social @who.int
@lancetgastrohep.bsky.social
😑 not all countries have national HCV action plans
☹️ 36% have (partial) restrictions on curative #HCV treatments
😑 30% met HCV #WHO diagnosis coverage target of 60%
☹️ only 15% met HCV #WHO treatment target
#GI #Endoscopy #IBD #CU #Colitis #CD #Crohn
❓which endoscopic score to you use❓
#MES #Mayo Endoscopic Score
#UCEIS Ulcerative Colitis Endoscopic Index of Activity
#Rutgeerts score for Grading Ileum Pathology
#PICcaSSo score for mucosal & vascular architecture
@AGA @CGH
🔗 tinyurl.com/s4xuwy93
❓which endoscopic score to you use❓
#MES #Mayo Endoscopic Score
#UCEIS Ulcerative Colitis Endoscopic Index of Activity
#Rutgeerts score for Grading Ileum Pathology
#PICcaSSo score for mucosal & vascular architecture
@AGA @CGH
🔗 tinyurl.com/s4xuwy93
May 20, 2025 at 12:24 PM
#GI #Endoscopy #IBD #CU #Colitis #CD #Crohn
❓which endoscopic score to you use❓
#MES #Mayo Endoscopic Score
#UCEIS Ulcerative Colitis Endoscopic Index of Activity
#Rutgeerts score for Grading Ileum Pathology
#PICcaSSo score for mucosal & vascular architecture
@AGA @CGH
🔗 tinyurl.com/s4xuwy93
❓which endoscopic score to you use❓
#MES #Mayo Endoscopic Score
#UCEIS Ulcerative Colitis Endoscopic Index of Activity
#Rutgeerts score for Grading Ileum Pathology
#PICcaSSo score for mucosal & vascular architecture
@AGA @CGH
🔗 tinyurl.com/s4xuwy93
@easlnews.bsky.social Studio during #EASLcongress 2025 in Amsterdam with discussions on therapeutic targets in decompensated #cirrhosis involving @debbieshawcross.bsky.social and representatives of @boehringerglobal.bsky.social and @genfit.bsky.social
May 12, 2025 at 7:39 PM
@easlnews.bsky.social Studio during #EASLcongress 2025 in Amsterdam with discussions on therapeutic targets in decompensated #cirrhosis involving @debbieshawcross.bsky.social and representatives of @boehringerglobal.bsky.social and @genfit.bsky.social
What a pleasure to meet many friends and colleagues during @easlnews.bsky.social #EASLcongress 2025 in Amsterdam.
A special last minute surprise was Prof. Tung-Hung Su from Taiwan.
A special last minute surprise was Prof. Tung-Hung Su from Taiwan.
May 11, 2025 at 12:32 PM
What a pleasure to meet many friends and colleagues during @easlnews.bsky.social #EASLcongress 2025 in Amsterdam.
A special last minute surprise was Prof. Tung-Hung Su from Taiwan.
A special last minute surprise was Prof. Tung-Hung Su from Taiwan.
@easlnews.bsky.social #HBV CPG# Guidance on
🛑 Stopping Nucleoside Analogon (NUC) Therapy in #HBV
(1) No immunusppression / no advanced liver disease (fibrosis)
(2) HBV-DNA suppression (< 3 years)
(3) HBsAg-Quant <1000 in Caucasians / <100 in Asians
🛑 Stopping Nucleoside Analogon (NUC) Therapy in #HBV
(1) No immunusppression / no advanced liver disease (fibrosis)
(2) HBV-DNA suppression (< 3 years)
(3) HBsAg-Quant <1000 in Caucasians / <100 in Asians
May 10, 2025 at 8:18 AM
@easlnews.bsky.social #HBV CPG# Guidance on
🛑 Stopping Nucleoside Analogon (NUC) Therapy in #HBV
(1) No immunusppression / no advanced liver disease (fibrosis)
(2) HBV-DNA suppression (< 3 years)
(3) HBsAg-Quant <1000 in Caucasians / <100 in Asians
🛑 Stopping Nucleoside Analogon (NUC) Therapy in #HBV
(1) No immunusppression / no advanced liver disease (fibrosis)
(2) HBV-DNA suppression (< 3 years)
(3) HBsAg-Quant <1000 in Caucasians / <100 in Asians
May 10, 2025 at 7:59 AM
April 18, 2025 at 7:45 AM
Welcome @cemm-vienna.bsky.social @bsky.app !!
The #HEPEX Lab @meduniwien.ac.at is part of #CeMM and investigates molecular mechanisms of #Fibrogenesis and #PortalHypertension
The #HEPEX Lab @meduniwien.ac.at is part of #CeMM and investigates molecular mechanisms of #Fibrogenesis and #PortalHypertension
April 14, 2025 at 8:49 AM
Welcome @cemm-vienna.bsky.social @bsky.app !!
The #HEPEX Lab @meduniwien.ac.at is part of #CeMM and investigates molecular mechanisms of #Fibrogenesis and #PortalHypertension
The #HEPEX Lab @meduniwien.ac.at is part of #CeMM and investigates molecular mechanisms of #Fibrogenesis and #PortalHypertension